MacroGenics, Inc. (NASDAQ:MGNX) is Under Analysts Radar as Broker Rating Hits 47

MacroGenics, Inc. (NASDAQ:MGNX) currently has an A verage Broker Rating of 1.55. This number is based on the 11 sell-side firms polled by Zacks. The ABR rank within the industry stands at 47. Analysts on a consensus basis are expecting that the stock will reach $30.11 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.

Stock analysis typically falls into two main categories. Some investors may prefer technical analysis, and others may prefer to study the fundamentals. Many investors will keep an eye on both. Technical analysis involves trying to project future stock price movements based on prior stock activity. Technicians strive to identify chart patterns and study other historical price and volume data. Technical investors look to identify trends when assessing a stock. The trend is typically considered to be the main direction of the share price. Trends are generally categorized as either up, down, or sideways. If a bullish trend is spotted, the trader may expect the upward trend to continue and thus try to capitalize on further upward action.

MacroGenics, Inc. (NASDAQ:MGNX) closed the last session at $19.13 and sees an average of 1228880.75 shares trade hands in each session. The 52-week low of the stock stands at $11.11 while the current level stands at 39.6% of the 52-week High-Low range. Looking further out we can see that the stock has moved 53.29% over the past 12 weeks and 50.63% year to date.

Research analysts are predicting that MacroGenics, Inc. (NASDAQ:MGNX) will report earnings of $-0.93 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Most recently MacroGenics, Inc. (NASDAQ:MGNX) posted quarterly earnings of $-1.06 which compared to the sell-side estimates of -0.98. The stock’s 12-month trailing earnings per share stands at $-4.24. Shares have moved $-9.42 over the past month and more recently, $0.31 over the past week heading into the earnings announcement. There are 7 analyst projections that were taken into consideration from respected brokerage firms.

8 analysts rate MacroGenics, Inc. a Buy or Strong Buy, which is 72.73% of all the analyst ratings.

When conducting stock analysis, investors have a wide array of various classifications to choose from. Growth stocks generally have the potential to produce above average profit growth and revenues. These types of stocks tend to expand quicker than the economy as a whole. Investors also have the option of adding cyclical stocks to the portfolio. Cyclicals are generally companies whose earnings and sales are highly correlated with that of the overall economy. When the economy is doing well, cyclical stocks may be more in favor. Investors may decide to go in another direction when the economy is dragging. When an economic downturn is underway, investors may choose to select defensive stocks. These types of stocks generally stand up well during down periods based on their insulation from the business cycle. Investors also have the option of purchasing foreign stocks to help add some diversity to the portfolio. 

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.